Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Assembly Puts Off “Fake” Drug Definition Opposed By India

This article was originally published in PharmAsia News

Executive Summary

The World Health Assembly has rejected temporarily a global definition of what constitutes counterfeit drugs, providing relief to Indian generics makers. Indian health activists and the government feared the assembly would adopt a proposed definition that would cover generics as well as fake drugs as part of an effort to reduce the surfeit of counterfeits. The assembly suggested its executive board take a closer look at the International Medical Products Anti-Counterfeiting Taskforce definition opposed by Indian drug makers and their government. Their objection is to the part that determines a medical product counterfeit when "there is a false representation in relation to its identity, history or source, applying to the product, its container, packaging or other labeling information." (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel